RecruitingBreast Cancer
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
Eligible age
18+ yrs
Accepts
All genders
Locations
5 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer. The main goals of this study are to: * Learn how well the combination of tucatinib and Doxil works * Learn more about the side effects of the combination of tucatinib and Doxil
Sponsor: SCRI Development Innovations, LLC
You may qualify if…
- ✓ Written informed consent, according to local guidelines, signed and dated by the patient or by a legal guardian prior to the performance of any study-specific procedures, sampling, or analyses
- ✓ At least 18 years-of-age at the time of signature of the informed consent form (ICF)
- ✓ Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
- ✓ Have a confirmed diagnosis of locally advanced/metastatic HER2+ breast cancer (based on local laboratory testing per American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines immunohistochemistry 3+ (IHC3+) or fluorescence in situ hybridization + (FISH+))
- ✓ Have had prior treatment with at least 1 line of anti-HER2 therapy for locally advanced/metastatic disease or relapsed within 6 months of completion of adjuvant anti-HER2 therapy. Prior treatment with tucatinib in the metastatic setting is allowed
- ✓ Measurable disease as measured by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
- ✓ Females of child-bearing potential should be using adequate contraceptive measures from the time of screening until 6 months following the last dose of study drug(s), should not be breast feeding and must have a negative pregnancy test prior to start of dosing, or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:
- ✓ Post-menopausal: defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments
You may not qualify if…
- ✕ Treatment with any of the following:
- ✕ Any systemic anti-cancer chemotherapy or small molecule, biologic, or hormonal agent from a previous treatment regimen or clinical study within 21 days or 5 half-lives (whichever is shorter) prior to the first dose of study drugs. At least 10 days must have elapsed between the last dose of such agent and the first dose of study drugs.
- ✕ Prior treatment with anthracycline in any setting
- ✕ Major surgery (excluding placement of vascular access) within 28 days of first dose of study drugs
- ✕ Palliative radiation therapy within 14 days of first dose of study drugs
- ✕ Based on screening brain MRI, patients must not have any of the following:
- ✕ Any untreated brain lesions \>2.0 cm in size, unless discussed with the Medical Monitor and approval for enrollment is granted
- ✕ Ongoing use of systemic corticosteroids for control of symptoms of brain metastases at a total daily dose of \>2 mg of dexamethasone (or equivalent). However, patients on a chronic stable dose of ≤2 mg total daily of dexamethasone (or equivalent) may be eligible with discussion and approval by the Medical Monitor
Where it's recruiting
Maryland
Columbia
Pennsylvania
Bensalem
Tennessee
Nashville
Texas
Dallas · San Antonio
Virginia
Norfolk · Salem
Source: ClinicalTrials.gov · NCT05748834 · last updated 2026-03-20